Plasma cell neoplasm
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes plasma cell myeloma, plasma cell leukemia, plasmacytoma, monoclonal immunoglobulin deposition disease, and monoclonal gammopathy of undetermined significance.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Plasma cell neoplasm
- Therapeutic area
- Hematology
- plasma cell neoplasm
- Neoplasm, Plasma Cell
- plasma cell dyscrasia
- Plasma Cell Neoplasms
- plasma cell tumor
- plasma cell tumor, malignant
- Plasma Cell Tumors
- plasmacytic neoplasm
- plasmacytic tumor
- plasmacytic tumour
- Severity
- Severe
- Hematology
- Immunology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0004959
- Parent condition
- MONDO:0004949
Related records
Broader conditions (17)
- B-cell neoplasm
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplasm of mature B-cells
- Neoplastic disease or syndrome
Narrower conditions (24)
- Alpha-heavy chain disease
- Delta-heavy chain disease
- Epsilon-heavy chain disease
- Extramedullary plasmacytoma
- Extramedullary soft tissue plasmacytoma
- Gamma-heavy chain disease
- Heavy chain deposition disease
- Heavy chain disease
- Indolent plasma cell myeloma
- Leukemoid reaction
- Light and heavy chain deposition disease
- Light chain deposition disease
- mu-heavy chain disease
- Non-amyloid monoclonal immunoglobulin deposition disease
- Non-secretory plasma cell myeloma
- Osteosclerotic plasma cell myeloma
- Plasma cell leukemia
- Plasma cell myeloma
- Plasmacytoma
- Primary plasmacytoma of the bone
Trials (705)
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 68Ga-BCMA PET/CT in Multiple Myeloma
- a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
- A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)
- A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
- A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
- A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
- A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
- A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Approved drugs (1)
- Idecabtagene vicleucel
Drugs in development (70)
- A27.15 Phase 1
- Allopurinol Phase 1
- Amifostine Phase 1
- Arsenic trioxide Phase 2
- Ascorbic acid Phase 2
- Bevacizumab Phase 2
- Bortezomib Phase 2
- Bryostatin 1 Phase 2
- Busulfan Phase 2
- Carboplatin Phase 1
- Carmustine Phase 2
- Cladribine Phase 1
- Cyclophosphamide Phase 3
- Cyclosporine Phase 2
- Cytarabine Phase 2
- Daclizumab Phase 2
- Dexamethasone Phase 3
- Docetaxel Phase 1
- Doxorubicin Phase 2
- Doxorubicin hydrochloride Phase 3